‘affect with the many rapid advances in lung adenocarcinoma clinical, radiologic, pathologic, molecular and surgical aspects of this cancer, it is necessary classification classification with an international multidisciplinary consensus committee,’said Dr. William Travis, the attending thoracic pathologist at Memorial Sloan Kettering Cancer Center in New York City. ‘Because lung cancer is the leading cause of cancer mortality worldwide and adenocarcinoma is the most common histologic subtype in most countries, should use this classification a major public health problem. ‘.. The new classification is published in the February issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer .
A completely new aspect of this division, which was not addressed in previous WHO classifications, a portion of the diagnosis and classification of non-small cell carcinoma in small biopsies and concerned concerned, Travis said. ‘This is important because 70 percent of lung cancers present at an advanced stage,’said Travis. ‘This section not only provides new criteria for the diagnosis of adenocarcinoma relative to squamous cell carcinoma, including the use of special stains in difficult cases, but also stressed the importance of preserving tissue for molecular studies. ‘.– – 70 per cent of of RA patients treated on biologics evaluate their pain than is less painful is now, if the disease was first diagnosed compared of patients treated with biologics, are 100 % satisfied with their treatment (77 % excellent;.